Baillie Gifford WW Health Innovation Fund Class B GBP AccRegistrati per vedere i rating |
Storico dei rendimenti | 29/02/2024 |
Crescita di 1000 (EUR) | Grafico Interattivo |
Sintesi | ||
NAV 28/03/2024 | GBP 7,491 | |
Var.Ultima Quotazione | 2,06% | |
Categoria Morningstar™ | Azionari Settore Salute | |
Categoria Assogestioni | - | |
Isin | IE00BD9MC568 | |
Fund Size (Mil) 28/03/2024 | USD 179,19 | |
Share Class Size (Mil) 28/03/2024 | GBP 50,14 | |
Entrata (max) | - | |
Spese correnti 14/02/2024 | 0,65% |
Obiettivo d'Investimento Dichiarato: Baillie Gifford WW Health Innovation Fund Class B GBP Acc |
The investment objective of the Fund is to provide strong returns over the long term by investing primarily in a global equity portfolio selected from companies engaged in the healthcare industry and that promotes better healthcare outcomes by driving real change for patients and the healthcare system and evidence care about patients. The Fund may also invest in other transferable securities, money market instruments, cash and cash equivalents. |
Rendimenti % (EUR) | |||||||||||||
|
Gestione | ||
Nome del Gestore Inizio Gestione | ||
Julia Angeles 01/10/2018 | ||
Marina Record 01/10/2018 | ||
Click here to see others | ||
Data di Partenza 08/07/2020 |
Pubblicità |
Indice | |
Benchmark Dichiarato | Indice di Categoria Morningstar |
MSCI ACWI NR EUR | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Composizione del Fondo Baillie Gifford WW Health Innovation Fund Class B GBP Acc | 31/01/2024 |
|
|
Primi 5 Titoli | Settore | % |
Moderna Inc | Salute | 6,89 |
Alnylam Pharmaceuticals Inc | Salute | 6,49 |
Genmab A/S | Salute | 6,04 |
ShockWave Medical Inc | Salute | 5,86 |
argenx SE | Salute | 5,74 |
Incremento Decremento Nuova Posizione | ||
Baillie Gifford WW Health Innovation Fund Class B GBP Acc |